A Postmenopausal Woman with Gross Cystic Disease Fluid Protein-15 and Estrogen Receptor-Positive Recurrence of Papillary Thyroid Cancer

Thyroid ◽  
2010 ◽  
Vol 20 (12) ◽  
pp. 1413-1417 ◽  
Author(s):  
Amanda Winters ◽  
Paul Friedlander ◽  
Bernard M. Jaffe ◽  
Mohamed Abdel Khalek ◽  
Krzysztof Moroz ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Postmenopausal Woman ◽  
Papillary Thyroid Cancer ◽  
Cystic Disease ◽  
Papillary Thyroid ◽  
Positive Recurrence ◽  
Estrogen Receptor Positive ◽  
Cystic Disease Fluid Protein

scholarly journals Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer

2016 ◽  
Vol 5 (4) ◽  
pp. 224-230 ◽  
Author(s):  
Giacomo Sturniolo ◽  
Carles Zafon ◽  
Mariacarla Moleti ◽  
Josep Castellví ◽  
Francesco Vermiglio ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Progesterone Receptor ◽  
Papillary Thyroid Cancer ◽  
Estrogen Receptor Α ◽  
Papillary Thyroid ◽  
Immunohistochemical Expression

scholarly journals Differential Effects of Estrogen Receptor Alpha and Beta on Endogenous Ligands of Peroxisome Proliferator-Activated Receptor Gamma in Papillary Thyroid Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Shucai Yang ◽  
Zhongqin Gong ◽  
Zhimin Liu ◽  
Minghui Wei ◽  
Lingbin Xue ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Cancer Cells ◽  
Papillary Thyroid Cancer ◽  
Estrogen Receptor Alpha ◽  
Peroxisome Proliferator ◽  
Papillary Thyroid ◽  
Peroxisome Proliferator Activated Receptor ◽  
Receptor Alpha ◽  
Induced Apoptosis

PurposeThe inhibition of estrogen receptor alpha (ERα) or the activation of ERβ can inhibit papillary thyroid cancer (PTC), but the precise mechanism is not known. We aimed to explore the role of ERα and ERβ on the production of endogenous peroxisome proliferator-activated receptor gamma (PPARγ) ligands in PTC.Methods2 PTC cell lines, 32 pairs of PTC tissues and matched normal thyroid tissues were used in this study. The levels of endogenous PPARγ ligands 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), 13-S-hydroxyoctadecadienoic acid (13(S)-HODE), and15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) were measured by ELISA.ResultsThe levels of PGJ2 and 15(S)-HETE were significantly reduced in PTC, but 13(S)-HODE was not changed. Activation of ERα or inhibition of ERβ significantly downregulated the production of PGJ2, 15(S)-HETE and 13(S)-HODE, whereas inhibition of ERα or activation of ERβ markedly upregulated the production of these three ligands. Application of endogenous PPARγ ligands inhibited growth, induced apoptosis of cancer cells, and promoted the efficacy of chemotherapy.ConclusionThe levels of endogenous PPARγ ligands PGJ2 and 15(S)-HETE are significantly decreased in PTC. The inhibition of ERα or activation of ERβ can inhibit PTC by stimulating the production of endogenous PPARγ ligands to induce apoptosis in cancer cells.

Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause

Surgery ◽  
2018 ◽  
Vol 163 (1) ◽  
pp. 143-149 ◽  
Author(s):  
Gustavo A. Rubio ◽  
Paola Catanuto ◽  
Marilyn K. Glassberg ◽  
John I. Lew ◽  
Sharon J. Elliot
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Receptor Subtype ◽  
Papillary Thyroid

scholarly journals Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer

2021 ◽  
Vol 10 (9) ◽  
pp. 1180-1188
Author(s):  
C Chiapponi ◽  
H Alakus ◽  
M Faust ◽  
A M Schultheis ◽  
J Rosenbrock ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Surgical Treatment ◽  
Papillary Thyroid Cancer ◽  
Fdg Pet ◽  
Radioiodine Therapy ◽  
External Beam Radiation ◽  
Papillary Thyroid ◽  
Beam Radiation ◽  
Positive Recurrence ◽  
The Impact

Purpose Five percent of patients with differentiated thyroid cancer are diagnosed with radioiodine refractory relapse in the course of the disease. For isolated or oligometastatic cervical recurrence, resection or another local treatment is recommended. In this study, the impact of surgical treatment of cervical radioiodine refractory 18F-FDG-PET positive relapse of papillary thyroid cancer (PTC) was evaluated. Methods Patients receiving radioiodine therapy between 2005 and 2015 at the University Hospital of Cologne, Germany, for PTC were screened. The subgroup of patients undergoing surgery during the course of disease after recommendation by a multidisciplinary endocrine team for cervical radioiodine refractory 18F-FDG-PET positive recurrence was identified. Demographics, clinic-pathologic characteristics, oncologic treatment, and outcome were analyzed. Results Thirty (3%) of 969 patients with PTC treated with radioiodine therapy at our institution underwent surgery for radioiodine refractory 18F-FDG-PET positive cervical recurrence during the course of the disease. In eight (26.6%) patients, more than one operation was performed. Sixteen (53%) patients received external beam radiation therapy (EBRT) after surgery. Follow-up was on average, 79.2 ± 61.6 months after the last surgical treatment. Biochemical and radiological cure was seen in 12 (40%) patients. Remission was significantly more frequent in younger patients (P = 0.0001) with lymph node rather than soft tissue tumor recurrence (P = 0.004). Conclusions Surgical treatment of radioiodine refractory 18F-FDG-PET positive cervical recurrence led to biochemical and radiological cure in about 40% of patients in this study. Further data are needed concerning risk stratification of potential subgroups benefitting of surgical approach and the possible role of EBRT after repetitive surgery.

Sign in / Sign up

Export Citation Format

Share Document